Beta-amyloid accumulation is thought to be a key factor in the progression of Alzheimer's disease. My laboratory focuses on mechanisms of beta-amyloid clearance. This project is focused on the study of a beta-amyloid degrading enzyme called SEP. The aims are 1) to determine the extent of SEP's importance to beta-amyloid clearance in vivo, 2) to explore the therapeutic potential of SEP using gene transfer therapy, and 3) to explore SEP expression levels related to Alzheimer's disease in human clinical brain samples. This work will expand our knowledge of mechanisms of beta-amyloid clearance as well as develop potential therapeutic and or diagnostic techniques for Alzheimer's disease.